Ensoma /en’sōmə/ is derived from the Greek phrase “en soma,” meaning in the body. We develop one-time in vivo treatments that precisely engineer any or all blood and immune cells to cure diseases from within. We have a bigger, bolder vision for genomic medicine: treatments as versatile, precise, and far-reaching as the body’s own cells. Our team takes inspired action towards pushing beyond today’s possible with the goal of delivering a one-time, off-the-shelf treatment to patients everywhere.
| Website | http://www.ensoma.com |
| Revenue | $6.3 million |
| Employees | 40 (35 on RocketReach) |
| Technologies |
JavaScript
,
HTML
,
PHP
+18 more
(view full list)
|
| Industry | Biotechnology Research |
| Keywords | Cell Therapy, Immunotherapy, Gene Editing, Immune Cell Therapy, Genome Editing, Genetic Engineering, Cell Engineering, Precision Medicine, Targeted Therapy, Regenerative Medicine, Biological Therapies, Rare Disease Treatment, Disease Treatment, Clinical Trials, Biotechnology, Pharmaceutical |
| Competitors | bluebird bio, CRISPR Therapeutics, Vertex Pharmaceuticals, Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Editas Medicine, Intellia Therapeutics, Inc., Provention Bio, a Sanofi Company, Regeneron, Novartis +42 more (view full list) |
Looking for a particular Ensoma employee's phone or email?
The Ensoma annual revenue was $6.3 million in 2026.
Paula Soteropoulos is the Chairman of the Board of Ensoma.
35 people are employed at Ensoma.
Ensoma is based in Boston, Massachusetts.